- Home
- CGNT vs GOSS Comparison
CGNT vs GOSS Comparison
Compare CGNT & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGNT
- GOSS
- Stock Information
- Founded
- CGNT 2020
- GOSS 2015
- Country
- CGNT Israel
- GOSS United States
- Employees
- CGNT N/A
- GOSS N/A
- Industry
- CGNT Computer Software: Prepackaged Software
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- CGNT Technology
- GOSS Health Care
- Exchange
- CGNT Nasdaq
- GOSS Nasdaq
- Market Cap
- CGNT 657.1M
- GOSS 586.6M
- IPO Year
- CGNT N/A
- GOSS 2019
- Fundamental
- Price
- CGNT $8.46
- GOSS $3.18
- Analyst Decision
- CGNT Hold
- GOSS Strong Buy
- Analyst Count
- CGNT 1
- GOSS 6
- Target Price
- CGNT N/A
- GOSS $8.60
- AVG Volume (30 Days)
- CGNT 289.4K
- GOSS 4.4M
- Earning Date
- CGNT 09-09-2025
- GOSS 11-06-2025
- Dividend Yield
- CGNT N/A
- GOSS N/A
- EPS Growth
- CGNT N/A
- GOSS N/A
- EPS
- CGNT N/A
- GOSS N/A
- Revenue
- CGNT $376,566,000.00
- GOSS $40,237,000.00
- Revenue This Year
- CGNT $14.94
- GOSS N/A
- Revenue Next Year
- CGNT $9.57
- GOSS $30.65
- P/E Ratio
- CGNT N/A
- GOSS N/A
- Revenue Growth
- CGNT 14.04
- GOSS N/A
- 52 Week Low
- CGNT $6.38
- GOSS $0.66
- 52 Week High
- CGNT $11.66
- GOSS $3.60
- Technical
- Relative Strength Index (RSI)
- CGNT 44.61
- GOSS 66.52
- Support Level
- CGNT $8.15
- GOSS $2.61
- Resistance Level
- CGNT $8.81
- GOSS $3.60
- Average True Range (ATR)
- CGNT 0.32
- GOSS 0.28
- MACD
- CGNT -0.02
- GOSS 0.07
- Stochastic Oscillator
- CGNT 21.83
- GOSS 65.71
About CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.